Trial Profile
A randomized, cross-over, open-label study of the cost-effectiveness of NeoRecormon [epoetin beta] administered subcutaneously or intravenously in dialysis patients with renal anemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2010
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary) ; Epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 27 Jun 2007 New trial record.